Qiuwei Pan


Room: Na-1005

Professional Experience
Qiuwei (Abdullah) Pan (1981) studied veterinary medicine & animal science at Northwest Minzu University, Lanzhou, China (2000-2004). After his Master research (2004-2007) on experimental therapy of liver cancer at Zhejiang Sci-Tech University in China, he moved to the Department of Gastroenterology and Hepatology, Erasmus MC Rotterdam, The Netherlands for his PhD research on hepatitis C virus (HCV) infection. Shortly after dissertation of his PhD thesis in 2012, he started to establish his own research group at the same laboratory. As a principal investigator (PI), he is currently leading a research group with 3 postdoc and over 10 PhD students.

His group dedicates to translational research of viral infections with focus on hepatitis E virus, rotavirus and norovirus. Meanwhile, he has also established a research line of liver cancer, which is mainly caused by hepatitis virus infection. By incorporating state-of-the-art molecular and cell biology, his research aims to contribute to the understanding of virus-host interactions, to the development of new antiviral therapies and to the better understanding of how hepatitis viruses causing liver carcinogenesis. His research has been supported by several (personal) grants (in total, approx. € 1,5 M), including the prestigious NWO/ZonMW Veni grant, a KWF young investigator grant, a Career Development Grant by the Dutch Digestive Disease Foundation, a Centennial fellowship by Daniel den Hoed Foundation and a Sheila Sherlock Fellowship from the European Association for the Study of the Liver. He has authored more than 100 publications with over 20 first and 60 last/corresponding authorships in peer-reviewed international journals. Importantly, his group has pioneered and made major contributions in translational research of hepatitis E. He is now dedicating in combating this disease in response to the global call towards the elimination of viral hepatitis by 2030.

Selected references:

         Wang W, Wang Y, Qu C, Wang S, Zhou J, Cao W, Xu L, Ma B, Hakim MS, Yin Y, Li T, Peppelenbosch MP, Zhao J, Pan Q*.

The RNA genome of hepatitis E virus robustly triggers antiviral interferon response. Hepatology. 2018 Jun;67(6):2096-2112. (Comprehensively described host interferon response to HEV infection in cell culture and in patients). https://www.ncbi.nlm.nih.gov/pubmed/29194722

Wanlu Cao, Kan Chen, Michiel Bolkestein, Yuebang Yin, Monique M. A. Verstegen, Marcel. J. C. Bijvelds, Wenshi Wang, Nesrin Tuysuz, Derk ten Berge, Dave Sprengers, Herold J. Metselaar, Luc J. W. van der Laan, Jaap Kwekkeboom, Ron Smits, Maikel P. Peppelenbosch and Qiuwei Pan*. Dynamics of Proliferative and Quiescent Stem Cells in Liver Homeostasis and Injury. Gastroenterology. 2017 Oct;153(4):1133-1147. (Expertise on liver organoid technology; the first to functionally demonstrate quiescent cells in the liver are stem cells)



    Wenshi Wang, Yuebang Yin, Lei Xu, Junhong Su, Fen Huang, Yijin Wang, Patrick P C Boor, Kan Chen, Wenhui Wang, Wanlu Cao, Xinying Zhou, Pengyu Liu, Luc J. W. van der Laan, Jaap Kwekkeboom, Maikel P. Peppelenbosch and Qiuwei Pan*

Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections. Science Signaling. 2017 Apr 25;10(476). pii: eaah4248. (Expertise on innate antiviral immune response; described the basal defense mechanisms against HEV infection)



        Xu L, Wang W, Li Y, Zhou X, Yin Y, Wang Y, de Man RA, van der Laan LJ, Huang F, Kamar N, Peppelenbosch MP, Pan Q*.

RIG-I is a key antiviral interferon-stimulated gene against hepatitis E virus regardless of interferon production. Hepatology. 2017 Jun;65(6):1823-1839. (Expertise on innate immune response against HEV infection; commented by an editorial)



    Yijin Wang, Xinying Zhou, Yannick Debing, Kan Chen, Luc J W Van der laan, Johan Neyts, Harry L A Janssen, Herold J. Metselaar, Maikel P. Peppelenbosch, Qiuwei Pan*.

Calcineurin Inhibitors Stimulate and Mycophenolic Acid Inhibits Replication of Hepatitis E Virus. Gastroenterology. 2014 Jun;146(7):1775-83. (Expertise on anti-HEV drug development; the first to demonstrate the direct effects of immunosuppressants on HEV and as an important reference for choosing the optimal immunosuppressive medication in HEV-infected organ transplant patients)



Pubmed search for Q. Pan: